SkinBioTherapeutics (LON:SBTX) Releases Earnings Results

SkinBioTherapeutics (LON:SBTX) announced its quarterly earnings results on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative net margin of 237.95% and a negative return on equity of 115.86%.

SkinBioTherapeutics Stock Down 4.5 %

SkinBioTherapeutics stock opened at GBX 22.20 ($0.29) on Wednesday. SkinBioTherapeutics has a 12 month low of GBX 8.32 ($0.11) and a 12 month high of GBX 26.45 ($0.34). The stock has a market capitalization of £50.71 million, a PE ratio of -13.65 and a beta of 2.01. The company has a debt-to-equity ratio of 27.57, a current ratio of 0.93 and a quick ratio of 10.01. The business has a 50 day simple moving average of GBX 19.67 and a 200-day simple moving average of GBX 16.46.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.